A year after its founding, Alpine Immune Sciences Inc. (AIS) sped to a $48 million series A round that was led by Orbimed Advisors and joined by Frazier Healthcare Partners and Alpine Bioventures. In January 2015, Alpine Bio founded and provided the seed funding for Seattle-based AIS, which is developing protein-based immunotherapies using its variant immunoglobulin domain, or vIgD, platform technology, to interact simultaneously with multiple targets in the immune synapse using a single molecule.